255 related articles for article (PubMed ID: 24019492)
21. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses.
Spivak-Kroizman T; Rotin D; Pinchasi D; Ullrich A; Schlessinger J; Lax I
J Biol Chem; 1992 Apr; 267(12):8056-63. PubMed ID: 1349015
[TBL] [Abstract][Full Text] [Related]
22. Regulation of the catalytic activity of the EGF receptor.
Endres NF; Engel K; Das R; Kovacs E; Kuriyan J
Curr Opin Struct Biol; 2011 Dec; 21(6):777-84. PubMed ID: 21868214
[TBL] [Abstract][Full Text] [Related]
23. Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases.
Niggenaber J; Hardick J; Lategahn J; Rauh D
J Med Chem; 2020 Jan; 63(1):40-51. PubMed ID: 31414802
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
[TBL] [Abstract][Full Text] [Related]
25. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
[TBL] [Abstract][Full Text] [Related]
26. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
28. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization.
Filosto S; Khan EM; Tognon E; Becker C; Ashfaq M; Ravid T; Goldkorn T
PLoS One; 2011; 6(8):e23240. PubMed ID: 21853092
[TBL] [Abstract][Full Text] [Related]
29. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
30. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
Tamirat MZ; Koivu M; Elenius K; Johnson MS
PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
Guha U; Chaerkady R; Marimuthu A; Patterson AS; Kashyap MK; Harsha HC; Sato M; Bader JS; Lash AE; Minna JD; Pandey A; Varmus HE
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14112-7. PubMed ID: 18776048
[TBL] [Abstract][Full Text] [Related]
33. A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation.
Baumdick M; Gelléri M; Uttamapinant C; Beránek V; Chin JW; Bastiaens PIH
Nat Commun; 2018 Sep; 9(1):3847. PubMed ID: 30242154
[TBL] [Abstract][Full Text] [Related]
34. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
36. Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Kim Y; Li Z; Apetri M; Luo B; Settleman JE; Anderson KS
Biochemistry; 2012 Jun; 51(25):5212-22. PubMed ID: 22657099
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
38. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
[TBL] [Abstract][Full Text] [Related]
39. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.
Chung BM; Raja SM; Clubb RJ; Tu C; George M; Band V; Band H
BMC Cell Biol; 2009 Nov; 10():84. PubMed ID: 19948031
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.
Ray P; Raghunathan K; Ahsan A; Allam US; Shukla S; Basrur V; Veatch S; Lawrence TS; Nyati MK; Ray D
J Biol Chem; 2020 Sep; 295(36):12661-12673. PubMed ID: 32669362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
